These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 20548045)

  • 41. Prognostic factors for multiple sclerosis: the importance of natural history studies.
    Ebers GC
    J Neurol; 2005 Sep; 252 Suppl 3():iii15-iii20. PubMed ID: 16170495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Databases in MS research: pitfalls and promises.
    Weinshenker BG
    Mult Scler; 1999 Aug; 5(4):206-11. PubMed ID: 10467376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NEDA treatment target? No evident disease activity as an actionable outcome in practice.
    Parks NE; Flanagan EP; Lucchinetti CF; Wingerchuk DM
    J Neurol Sci; 2017 Dec; 383():31-34. PubMed ID: 29246616
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.
    Whitaker JN; McFarland HF; Rudge P; Reingold SC
    Mult Scler; 1995 Apr; 1(1):37-47. PubMed ID: 9345468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapies for multiple sclerosis: translational achievements and outstanding needs.
    Haghikia A; Hohlfeld R; Gold R; Fugger L
    Trends Mol Med; 2013 May; 19(5):309-19. PubMed ID: 23582699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis.
    Cottrell DA; Kremenchutzky M; Rice GP; Hader W; Baskerville J; Ebers GC
    Brain; 1999 Apr; 122 ( Pt 4)():641-7. PubMed ID: 10219777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatric Multiple Sclerosis.
    Lee JY; Chitnis T
    Semin Neurol; 2016 Apr; 36(2):148-53. PubMed ID: 27116721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An update on managing patients with multiple sclerosis in primary care.
    Hardeman P
    JAAPA; 2024 Feb; 37(2):22-29. PubMed ID: 38230895
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The natural history of multiple sclerosis: implications for trial design.
    Wingerchuk DM; Weinshenker BG
    Curr Opin Neurol; 1999 Jun; 12(3):345-9. PubMed ID: 10499179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.
    Weinshenker BG; Rice GP; Noseworthy JH; Carriere W; Baskerville J; Ebers GC
    Brain; 1991 Apr; 114 ( Pt 2)():1057-67. PubMed ID: 2043941
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The History of Diagnosis and Treatment of MS: a Brief Overview.
    Murray TJ
    Curr Neurol Neurosci Rep; 2022 Aug; 22(8):545-549. PubMed ID: 35699900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Observational data: Understanding the real MS world.
    Kalincik T; Butzkueven H
    Mult Scler; 2016 Nov; 22(13):1642-1648. PubMed ID: 27270498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Some recent advances in multiple sclerosis.
    McCarthy C; Thorpe J
    J Neurol; 2016 Sep; 263(9):1880-6. PubMed ID: 27113601
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact.
    Bebo BF; Fox RJ; Lee K; Utz U; Thompson AJ
    Mult Scler; 2018 Apr; 24(5):579-586. PubMed ID: 28279128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term care of patients with multiple sclerosis: a neurologist's perspective.
    Rose AS
    Neurology; 1980 Jul; 30(7 Pt 2):59-60. PubMed ID: 6771679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The spectrum of multiple sclerosis.
    Heard RN
    Curr Allergy Asthma Rep; 2007 Jul; 7(4):280-4. PubMed ID: 17547850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple Sclerosis in the Contemporary Age: Understanding the Millennial Patient with Multiple Sclerosis to Create Next-Generation Care.
    Hansen MR; Okuda DT
    Neurol Clin; 2018 Feb; 36(1):219-230. PubMed ID: 29157401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intermittent and periodic fasting - Evidence and perspectives in multiple sclerosis.
    Lorefice L; Pitzalis M; Zoledziewska M
    Mult Scler Relat Disord; 2024 Aug; 88():105744. PubMed ID: 38914047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bayesian analysis: what does it add to studies of the natural history of MS?
    Weinshenker BG
    J Neurol Sci; 2001 Aug; 189(1-2):1-2. PubMed ID: 11535227
    [No Abstract]   [Full Text] [Related]  

  • 60. Therapeutics of multiple sclerosis.
    Noseworthy JH
    Clin Neuropharmacol; 1991 Feb; 14(1):49-61. PubMed ID: 2029693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.